Anagrelide

Drug #2203

Anagrelide is a drug which reduces blood platelet count. This mechanism is still under analysis that how it reduces the blood platelets. The research work on patients supports the hypothesis of dose-related reduction in platelet production followed a decrease in megakaryocyte hypermaturation.

← Previous drug Next drug →

Primary Characteristics

It belongs to Platelet-reducing agent. pharmacological group on the basis of mechanism of action.

Molecular Weight: 255 · Solubility in Water: 2.50e-01 mg/mL · Non-proprietary name: Anagrelide.

Pharmacokinetics

None recorded.

Indications

Anagrelide is primarily indicated in conditions like Chronic myeloid leukaemia, Thrombocythaemia.

Anagrelide is also indicated for secondary conditions like Myeloproliferative disorders, Thrombosis.

Contraindications

Anagrelide is contraindicated in conditions like Hypersensitivity.

Dosage

Anagrelide's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
0.5 mg	0.5 mg	Every 6h	PO	This is the recomended starting dose. For one week. It is recommended that patients with moderate hepatic impairment start anagrelide therapy at a dose of 0.5 mg/day and be maintained for a minimum of one week with careful monitoring of cardiovascular effects. The dosage increment must not exceed more than 0.5 mg/day in any one-week. To monitor the effect of anagrelide and prevent the occurrence of thrombocytopenia, platelet counts should be performed every two days during the first week of treatment and at least weekly thereafter until the maintenance dosage is reached.
1 mg	1 mg	Every 12h	PO	This can also be the starting dose. For one week. Dosage should not exceed 10 mg/day or 2.5 mg in a single dose. To monitor the effect of anagrelide and prevent the occurrence of thrombocytopenia, platelet counts should be performed every two days during the first week of treatment and at least weekly thereafter until the maintenance dosage is reached.
0.1 %	0.1 %	Every 24h	Topical	0.1% may be used with caution in pediatric patients 1 year of age or older. The safety and efficacy of drug use for longer than 3 weeks in this population have not been established.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

3 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

The signs and symptoms that are produced after acute overdosage of Anagrelide are Peripheral edema.

Anagrelide is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, Anorexia , Asthenia , Back pain, Chest pain, Cough , Diarrhea, Dizziness, Dyspepsia , Dyspnea, Edema, Fever, Flatulence, Headache, Malaise, Nausea, Pain , Palpitation, Paresthesias, Pharyngitis, Pruritus , Rashes , Tachycardia, Vomiting .

Warnings / Precautions

Anagrelide should be used with caution in patients with known or suspected heart disease, and only if the potential benefits of therapy outweigh the potential risks. The potential risks and benefits of anagrelide therapy in a patient with mild and moderate impairment of hepatic function should be assessed before treatment is commenced. There are no special requirements for dosing the geriatric population.

Interference in Pathology

Anagrelide may interfere in the diagnosis of SGPT level disturbance. , SGOT level disturbance.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Caps

0.5 mg

Storage Conditions

Anagrelide should be stored Caps.

Drug Classification

1.10.2 — Anticoagulants/Platelet deaggregators

Manufacturers

Manufacturers of Anagrelide in Pakistan:

Atco